#最小單位貼紙

抗病毒藥品 Chronic hepatitis C: Genotype 1, 2, 3, 4, 5, or 6 infection in adults with or without compensated cirrhosis, or in combination with ribavirin in patients with decompensated cirrhosis

Antihepaciviral, NS5A Inhibitor; Antihepaciviral, Polymerase Inhibitor (Anti-HCV); NS5A Inhibitor; NS5B RNA Polymerase Inhibitor

1. Protein binding: (Velpatasvir) >99.5%; (Sofosbuvir) 61-65%
2. Metabolism: (Velpatasvir) Hepatic; substrate of P-gp, OATPs, and CYP2B6, CYP2C8, and CYP3A4; (Sofosbuvir) Hepatic; forms pharmacologically active nucleoside analog triphosphate GS-461203; dephosphorylation results in the formation of nucleoside inactive metabolite GS-331007
3. Half-life elimination: (Velpatasvir) 15 hours; (Sofosbuvir) 0.5 hours
4. Time to peak: (Velpatasvir) 3 hours; (Sofosbuvir) 0.5 to 1 hour
5. Excretion: (Velpatasvir) Urine: 0.4%, feces: 94%; (Sofosbuvir) Urine: 80%; feces: 14%

There are no contraindications listed in the manufacturer's labeling.

Fetal risk cannot be ruled out.

Infant risk cannot be ruled out.

Nausea, Headache, Fatigue

One tablet once daily for 12 weeks

Safety and effectiveness of sofosbuvir/velpatasvir are not established in pediatric patients

1. eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.
2. eGFR <30 mL/minute/1.73 m2, ESRD (including hemodialysis): There are no dosage adjustments provided in the manufacturer's labeling. However, sofosbuvir and metabolite accumulate in patients with severe renal impairment.

Mild, moderate, or severe impairment (Child-Pugh class A, B, or C): No dosage adjustment necessary.

Store in original container below 30 degrees C